Shihe Hou

792 total citations
25 papers, 624 citations indexed

About

Shihe Hou is a scholar working on Cancer Research, Oncology and Molecular Biology. According to data from OpenAlex, Shihe Hou has authored 25 papers receiving a total of 624 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Cancer Research, 9 papers in Oncology and 7 papers in Molecular Biology. Recurrent topics in Shihe Hou's work include PI3K/AKT/mTOR signaling in cancer (5 papers), Renal cell carcinoma treatment (4 papers) and NF-κB Signaling Pathways (4 papers). Shihe Hou is often cited by papers focused on PI3K/AKT/mTOR signaling in cancer (5 papers), Renal cell carcinoma treatment (4 papers) and NF-κB Signaling Pathways (4 papers). Shihe Hou collaborates with scholars based in United States, Switzerland and Paraguay. Shihe Hou's co-authors include Robert P. Ricciardi, Hancheng Guan, Neil Desai, Denis A. Smirnov, Anita N. Schmid, Daniel W. Pierce, Lee D. Cranmer, Nianhang Chen, Vinod Ravi and Richard F. Riedel and has published in prestigious journals such as Journal of Biological Chemistry, Journal of Clinical Oncology and Journal of the American College of Cardiology.

In The Last Decade

Shihe Hou

23 papers receiving 620 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Shihe Hou United States	13	235	212	141	131	111	25	624
Yingjun Su China	10	341 1.5×	382 1.8×	252 1.8×	109 0.8×	55 0.5×	21	900
Chongkui Sun China	13	337 1.4×	192 0.9×	125 0.9×	124 0.9×	62 0.6×	16	621
Jean Claude Monboisse France	9	280 1.2×	181 0.9×	81 0.6×	223 1.7×	58 0.5×	13	628
Xavier Canron France	11	614 2.6×	285 1.3×	75 0.5×	136 1.0×	56 0.5×	12	879
Jean‐Baptiste Oudart France	11	243 1.0×	197 0.9×	74 0.5×	171 1.3×	121 1.1×	32	578
Christine Mehner United States	14	423 1.8×	339 1.6×	96 0.7×	284 2.2×	77 0.7×	23	849
Catherine F. Welsh United States	14	470 2.0×	306 1.4×	108 0.8×	149 1.1×	61 0.5×	24	858
Camille L. Duran United States	12	347 1.5×	169 0.8×	133 0.9×	167 1.3×	50 0.5×	23	646

Countries citing papers authored by Shihe Hou

Since Specialization

Citations

This map shows the geographic impact of Shihe Hou's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Shihe Hou with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Shihe Hou more than expected).

Fields of papers citing papers by Shihe Hou

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Shihe Hou. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Shihe Hou. The network helps show where Shihe Hou may publish in the future.

Co-authorship network of co-authors of Shihe Hou

This figure shows the co-authorship network connecting the top 25 collaborators of Shihe Hou. A scholar is included among the top collaborators of Shihe Hou based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Shihe Hou. Shihe Hou is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Hou, Shihe, et al.. (2024). Antitumor activity of nab-sirolimus versus mTOR inhibitors temsirolimus, sirolimus, and everolimus in A549 NSCLC xenografts.. Journal of Clinical Oncology. 42(16_suppl). e15096–e15096.

Hou, Shihe, et al.. (2024). Abstract 6486: Correlation of nab-sirolimus tumor drug levels and improved tumor suppression in KRAS G12C non-small cell lung cancer xenografts treated with nab-sirolimus in combination with KRAS inhibitors. Cancer Research. 84(6_Supplement). 6486–6486. 1 indexed citations

Hou, Shihe, Heng Du, Anita N. Schmid, David J. Kwiatkowski, & Neil Desai. (2021). Abstract P138: nab-Sirolimus improves mTOR pathway suppression and antitumor activity versus oral mTOR inhibitors in PTEN null bladder cancer (UMUC3) and TSC2 null liver cancer (SNU398) xenografts. Molecular Cancer Therapeutics. 20(12_Supplement). P138–P138. 2 indexed citations

Wagner, Andrew J., Vinod Ravi, Richard F. Riedel, et al.. (2021). nab-Sirolimus for Patients With Malignant Perivascular Epithelioid Cell Tumors. Journal of Clinical Oncology. 39(33). 3660–3670. 100 indexed citations

Wagner, Andrew J., Vinod Ravi, Richard F. Riedel, et al.. (2020). Long-term follow-up for duration of response (DoR) after weekly nab-sirolimus in patients with advanced malignant perivascular epithelioid cell tumors (PEComa): Results from a registrational open-label phase II trial, AMPECT.. Journal of Clinical Oncology. 38(15_suppl). 11516–11516. 13 indexed citations

Sharma, Sunil, E. Gabriela Chiorean, Angela Alistar, et al.. (2020). Phase I results from a phase 1/2 multi-center study of nab-sirolimus combined with mFOLFOX6+bevacizumab (FB) as first-line (1L) therapy in patients (pts) with metastatic colorectal cancer (mCRC) with or without PTEN loss.. Journal of Clinical Oncology. 38(15_suppl). e16050–e16050. 1 indexed citations

Simon, Marc A., Mardi Gomberg‐Maitland, Ronald J. Oudiz, et al.. (2019). PATIENTS WITH SEVERE PULMONARY ARTERIAL HYPERTENSION TREATED WITH ABI-009, NAB-SIROLIMUS, AN MTOR INHIBITOR: INTERIM RESULTS FROM A PHASE 1 CLINICAL TRIAL. Journal of the American College of Cardiology. 73(9). 1927–1927. 2 indexed citations

Hou, Shihe, Anita N. Schmid, & Neil Desai. (2019). Abstract 3896: Distinct pharmacokinetics, tissue distribution and CNS penetration of ABI-009 (nab-Sirolimus). Cancer Research. 79(13_Supplement). 3896–3896. 1 indexed citations

Kesari, Santosh, Tiffany Juarez, Jose Carrillo, et al.. (2019). RBTT-01. A PHASE 2 TRIAL WITH ABI-009 (NAB-SIROLIMUS) AS SINGLE-AGENT AND COMBINATIONS IN RECURRENT HIGH-GRADE GLIOMA (rHGG) AND IN NEWLY DIAGNOSED GLIOBLASTOMA (ndGBM). Neuro-Oncology. 21(Supplement_6). vi218–vi219. 7 indexed citations

10.

Sharma, Sunil, Carlos Becerra, Marc Matrana, et al.. (2019). A phase I/II multicenter study of ABI-009 (nab-sirolimus) combined with FOLFOX and bevacizumab as first-line (1L) therapy in patients (pts) with metastatic colorectal cancer (mCRC) with or without PTEN loss.. Journal of Clinical Oncology. 37(4_suppl). TPS730–TPS730.

11.

Rajeshkumar, N.V., Shinichi Yabuuchi, Shweta Pai, et al.. (2016). Superior therapeutic efficacy of nab-paclitaxel over cremophor-based paclitaxel in locally advanced and metastatic models of human pancreatic cancer. British Journal of Cancer. 115(4). 442–453. 42 indexed citations

12.

Chen, Nianhang, Carrie Baker Brachmann, Xiping Liu, et al.. (2015). Albumin-bound nanoparticle (nab) paclitaxel exhibits enhanced paclitaxel tissue distribution and tumor penetration. Cancer Chemotherapy and Pharmacology. 76(4). 699–712. 89 indexed citations

13.

Abu‐Khalaf, Maysa, Megan Baumgart, Scott Gettinger, et al.. (2015). Phase 1b study of the mammalian target of rapamycin inhibitor sirolimus in combination with nanoparticle albumin–bound paclitaxel in patients with advanced solid tumors. Cancer. 121(11). 1817–1826. 11 indexed citations

14.

Schlaepfer, David D., Shihe Hou, Ssang‐Taek Lim, et al.. (2007). Tumor Necrosis Factor-α Stimulates Focal Adhesion Kinase Activity Required for Mitogen-activated Kinase-associated Interleukin 6 Expression. Journal of Biological Chemistry. 282(24). 17450–17459. 49 indexed citations

15.

Guan, Hancheng, Shihe Hou, & Robert P. Ricciardi. (2005). DNA Binding of Repressor Nuclear Factor-κB p50/p50 Depends on Phosphorylation of Ser337 by the Protein Kinase A Catalytic Subunit. Journal of Biological Chemistry. 280(11). 9957–9962. 84 indexed citations

16.

Hou, Shihe, Hancheng Guan, & Robert P. Ricciardi. (2003). Phosphorylation of Serine 337 of NF-κB p50 Is Critical for DNA Binding. Journal of Biological Chemistry. 278(46). 45994–45998. 78 indexed citations

17.

Zhao, Biwei, Shihe Hou, & Robert P. Ricciardi. (2003). Chromatin repression by COUP-TFII and HDAC dominates activation by NF-κB in regulating major histocompatibility complex class I transcription in adenovirus tumorigenic cells. Virology. 306(1). 68–76. 17 indexed citations

18.

Hou, Shihe, Hancheng Guan, & Robert P. Ricciardi. (2002). In Adenovirus Type 12 Tumorigenic Cells, Major Histocompatibility Complex Class I Transcription Shutoff Is Overcome by Induction of NF-κB and Relief of COUP-TFII Repression. Journal of Virology. 76(7). 3212–3220. 16 indexed citations

19.

Smirnov, Denis A., Shihe Hou, Xiaohong Liu, et al.. (2001). COUP-TFII Is Up-regulated in Adenovirus Type 12 Tumorigenic Cells and Is a Repressor of MHC Class I Transcription. Virology. 284(1). 13–19. 22 indexed citations

20.

Smirnov, Denis A., Shihe Hou, & Robert P. Ricciardi. (2000). Association of Histone Deacetylase with COUP-TF in Tumorigenic Ad12-Transformed Cells and Its Potential Role in Shut-Off of MHC Class I Transcription. Virology. 268(2). 319–328. 37 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact